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A B S T R A C TEffective pursuit of the science and management of heterogeneity of
treatment effect (HTE) relies on the mutual understanding of the
perspectives of, and collaboration among, the various stakeholders in
health care. In this article, we compare, contrast, and endeavor to ﬁnd
areas of alignment across the perspectives of three such stakeholders —
regulators, the biopharmaceutical and device industry, and U.S. payers.
First, we discuss how evidence of HTE is generated and could be
improved upon. For pharmaceuticals, much of the initial research is
conducted by the pharmaceutical industry, guided by basic science but
also delimited by potential markets, regulatory approval requirements,
trial size considerations, and payer expectations for evidence of value.
Once a drug is marketed, further evidence can be generated via combin-
ing trial data, conducting meta-analysis, and analyzing real-world results
through observational research designs; we explore how these efforts can
beneﬁt from cooperation across these stakeholders. Second, we discuss
the equally important utilization of HTE evidence so that physicians and
patients have access to and can beneﬁt from the learnings from this
research. Research ﬁndings must be translated into actionable informa-see front matter Copyright & 2013, International S
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13, New York, NY 10017, USA.tion and guidelines that can be incorporated into everyday practice.
Doing so requires interaction and collaboration among all involved, based
on facilitated communication as well as further evaluation research. We
provide examples of several cross-sectorial initiatives that are under way
in this area. Finally, we explore some economic aspects of HTE research
as part of the drug development, marketing, and treatment process.
Understanding the economic incentives present is fundamental to
aligning those incentives to improve the availability and utilization of
HTE evidence. Clear understandings among regulators, pharma, and
payers about high-value targets, methods to efﬁciently generate and
communicate information, and value propositions can lead to “win-win”
scenarios for patients, individual payers, the health care system overall,
and the future of drug development in producing new medicines.
Keywords: collaborative research, heterogeneity of treatment effect,
personalized medicine.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
As our understanding of the pathophysiology and genetics
behind disease and its related therapies has expanded, our
appreciation for the variations in effectiveness of different treat-
ments in diverse patient populations has also grown. While
heterogeneity of treatment effect (HTE) has been an important
element of medical decision making for quite some time, the
burgeoning area now often referred to as “personalized medicine”
is a more recent phenomenon. It is no longer just the realm of
academic researchers interested in the basic science, or those
most affected in everyday practice—physicians and their
patients. All sectors of the health care world, including policy
regulators, payers, and the pharmaceutical, biotech, and medical
device industry, are taking a major interest in this expanding
ﬁeld. HTE per se includes both treatments speciﬁcally deﬁned by
diagnosis using genetic or other biomarker information and moretraditional approaches using clinical or phenotypic stratiﬁers
such as demographic characteristics, disease severity, comorbid-
ities, previous response to treatment, side-effect tolerance,
behavioral characteristics, and patient/caregiver preferences [1–
3]. Improved understanding of HTE is a key enabler of the growth
of personalized medicine.
For effective progress in generating and applying evidence
about HTE to improve patient care, from the underlying science
to frontline practice setting, there needs to be agreement about
the type of evidence needed, about methods by which it is
generated, evaluated, and communicated, and ultimately about
how it is put into practice. There also need to be effective and
aligned economic incentives to generate and use that evidence
across the health care continuum. The three primary sectors
mentioned previously—regulators, payers, and the pharmaceut-
ical, biotech, and medical device industry—are key players in
generating, interpreting, and applying HTE-related evidence on aociety for Pharmacoeconomics and Outcomes Research (ISPOR).
o conﬂicts of interest with regard to the contents of this article.
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one views these areas. To that end, a session at the May 2011
ISPOR conference was organized, in which each sector’s perspec-
tives were represented and discussed [4]. This article is drawn
from the presentations and discussion at that session.
This article is organized into three sections—evidence gen-
eration, evidence utilization, and economics. The perspectives of
each sector are integrated into each section as appropriate. They
are followed by a discussion of selected areas for further consid-
eration and a conclusion.
Evidence Generation
Evidence from clinical trial and related sources
Before a new product is approved, incentives to detect HTE are
present but, until fairly recently, have been distinctly muted.
From a regulatory perspective, it is well known that using the
mean outcome effects from clinical studies does not necessarily
paint the full picture of the safety and efﬁcacy proﬁle of the drug,
and that using subgroup analysis is one way of identifying HTE
[5]. In some cases, the manufacturer may know that delineating
subgroup effects is an important way to differentiate the product
and wish to see such differentiation recognized in product label-
ing; when genetic differences in diseases and their treatments
are scientiﬁcally understood, they can be prima facie criteria for
differentiation (e.g., HER2, K-ras genetic differences in cancer).
Payers often would like to reduce the budget impact of a new
product by limiting the population to be treated. Approval bodies
such as UK’s National Institute for Health and Care Excellence
and the German Federal Joint Committee (GBA) have prospective
criteria for considering subgroup differences in their review beca-
use such differences may affect the cost-effectiveness or relative
effectiveness of the product [6].
Important factors, however, work against extensive or explor-
atory HTE analysis during this preapproval period. Lacking a clear
scientiﬁc or genetic basis for differentiation, regulatory authorities
(e.g., Food and Drug Administration [FDA] and European Medicines
Agency) may be skeptical of such claims and prefer to see a product
evaluated in the broader population in which it may be used.
Manufacturers are more generally inclined to have their products
available to larger patient populations unless there are compelling
reasons that they need to be limited. In a practical sense, HTE
detection often needs large overall sample sizes, but the more
patients are included, the more expensive and longer trials
become, and analysis of HTE can make submissions more complex
both to create and to review. Neither regulatory bodies nor
manufacturers are anxious to delay the availability of an effective
new product to patients without a good a priori reason that HTE is
likely to be present, and so such analysis is often not part of a
preagreed development or regulatory review plan. Nevertheless,
many manufacturers are now actively investigating HTE potential
in early research and development, via genomewide association
studies, predictive modeling, and other methods, as a basis for
subsequent development planning. In fact, more than 50% of
manufacturers have incorporated pharmacogenomics or pharma-
cogenetic diagnostics into their clinical development programs [7].
Once a product has gone through FDA review and is marketed,
the potential to detect HTE improves both due to data availability
on product usage and due to the methods that can be applied,
especially if different sectors are willing to collaborate in data
access and analytic efforts. As more randomized controlled trials
(RCTs) are performed, either by the sponsor or by independent
researchers, under certain circumstances individual patient data
from those trials can be pooled for analyses [8].
While analysis of individual patient data allows for the most
detailed analysis of HTE and other comparative effectiveness
research questions, access to such data may be quite limited, andthe programming and analysis effort is substantial. A more
broadly available and classic approach is meta-analysis, and
given the increasing number of online journals as well as the
results posted on clinicaltrials.gov, the extent of trial results
available for meta-analyses is expanding rapidly. Reporting of
subgroup results, however, is still quite variable. Uniform guide-
lines for reporting subgroup results, perhaps deﬁned within
disease area, would be helpful, as would guidelines and utilities
for interinvestigator cooperation in making unpublished sub-
group results available for meta-analyses.
Of course, real-world evidence also begins to accumulate as
utilization of the product grows following marketing approval.
Such data become a valuable but more analytically challenging
source of information on HTE, as discussed in more detail later.
Given these different approaches, systematic evidence reviews,
such as those sponsored by the Agency for Healthcare Research
and Quality, can begin to parse the extant research and reﬁne any
conclusions about HTE. The more good quality research is
available—a situation that could be enhanced by clear standards
for HTE research, whether with RCT or real-world data—the more
comprehensive and deﬁnitive these reviews can be.Evidence from real-world data
Real-world evidence demands about the safety, effectiveness, and
value associated with biopharmaceutical interventions and devi-
ces change as they enter the marketplace. Initially payers, physi-
cians, and other health care providers (HCPs) as well as patients
must rely on the evidence of safety and efﬁcacy from the pivotal
clinical trials that are available at the time of product launch. Once
a product is on the market, however, real-world evidence about
the product begins to accumulate rapidly in administrative claims
databases, electronic medical record (EMR) systems, and disease
and product registries. Real-world data are of great interest to
payers, physicians, and manufacturers because it reﬂect the
experiences of patient populations who are treated in actual
clinical practice rather than the narrowly deﬁned patient popula-
tions studied in clinical trials. Real-world data enable the analysis
of variation in medication adherence on health outcomes and
health care costs, the analysis of variation in physician treatment
patterns, the observation of patient experiences on new treat-
ments as they come on the market, treatment effectiveness in
patient groups typically not eligible for clinical trials such as those
with multiple comorbid conditions and hence multiple comedica-
tions, and many other questions that remain unanswered by RCT.
Databases capturing real-world evidence of health care treat-
ments, outcomes, and utilization enable analysis of large patient
populations at relatively low cost and without the delays asso-
ciated with primary data collection. However, there are well-
recognized challenges and limitations with the analysis of these
types of observational data that can lead to erroneous conclu-
sions. As data systems evolve and become more integrated, some
of these issues will be corrected, as controlling for confounders
will be facilitated by the increasing availability of integrated
clinical data. For example, the lack of clinical severity measures
in medical claims data could be addressed by linking medical
claims data with EMRs. In turn, this would address the general
lack of health care utilization data across treatment sites typical
of most EMR systems. There are several reasons to expect data
systems to continue to evolve rapidly over the next several years.
For example, in the United States, the Health Information Tech-
nology for Economic and Clinical Health Act (February 17, 2009)
contained signiﬁcant economic incentives for providers to adopt
meaningful use of EMR systems (as well as penalties if they do
not). This is leading to rapid growth in the use of EMRs, which will
enhance the technical ability to link EMRs and medical claims
data. Similarly, experimentation with new care delivery models
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of health information exchanges that enable the electronic ﬂow of
information among provider and payer organizations. These data
contain both clinical and health care utilization information.
Even with improvements in data systems, however, the
analysis of observational data generally requires the use of
sophisticated multivariate statistical methods to draw reliable
conclusions. These methods are well established, but best prac-
tice regarding the analysis of observational data continues to
evolve and results are not as uniformly accepted as randomized
controlled clinical trials [9]. Despite the challenges associated
with drawing conclusions from observational data, payer organ-
izations rely on such data to review (and sometimes alter) initial
coverage and reimbursement decisions, as do regulatory agencies
in monitoring product safety.
Unfortunately, data availability, speciﬁcally integrated data,
can be a signiﬁcant challenge in generating evidence that payers,
physicians, and patients require with respect to treatment safety,
effectiveness, and value. In some regions, real-world data do not
exist. It is more often the case, however, that the data exist but are
not directly accessible. For example, a regional health system
within a country may have clinical or claims data on its patients
but these data may be accessible only through an academic
intermediary. Even when data are available, as with the commer-
cially available medical claims or EMR databases in the United
States, they may be incomplete in various ways (e.g., lack infor-
mation on clinical severity, as well as lack of linkage of claims and
EMR data) that create potential biases in drawing inferences from
observational data. As a result of these issues, there is interest in
developing disease registries in Europe (Innovative Medicines
Initiative, see below) and the United States [10,11].Toward collaboration in evidence generation for HTE
Several efforts to combine individual patient data across data
sources are already in progress. The Partnership in Applied
Comparative Effectiveness Studies, sponsored by the FDA, is
one such project [12]. It combines premarketing data, RCT data
submitted to the FDA, with a variety of postmarketing data, such
as Medicare, Medicaid, and commercial insurance claims data. Its
aim is to provide a comprehensive framework for analyzing HTE
as part of comparative effectiveness research, both through
combining data sources and through standard and more
advanced analytical methods. It is being pursued via a partner-
ship including the Center for Medical Technology Policy, Johns
Hopkins University, the Lewin Group, and Buccaneer Computer
Systems and Services. Several projects are already under way.
The FDA is also involved in a number of other database and
analysis projects, including Sentinel, the Medical Device Epide-
miological Network, and the Observational Medical Outcomes
Partnership [13,14]. Another, purely private sector collaboration
has IMS Health partnering with Blue Health Intelligence to build a
real-world evidence platform to support epidemiological studies,
comparative effectiveness research, safety research, and com-
mercial analytics [15]. In Europe, the Innovative Medicines Ini-
tiative supports collaborative research projects and is fostering
the development of networks between life science companies
and academic experts in Europe with the goal to encourage
pharmaceutical innovation in development. It is a joint under-
taking between the European Union and the European Federation
of Pharmaceutical Industries and Associations [16].
Across these efforts, an important goal is to improve detection
of HTE in both the beneﬁts and the risks of product use, to identify
characteristics of responders versus nonresponders, and to dis-
tinguish average versus marginal treatment effects along various
patient and risk characteristics [17]. For these goals to be achieved,
however, there is much room for improvement in the collection ofsome less quantiﬁable outcomes, such as pain, of disease severity
measures, as well as less objective but highly informative factors
as physician and patient reasons for seeking or prescribing certain
treatments. There is also a growing array of methods guidelines to
assist researchers when combining diverse data sets, analyzing
observational data, or investigating HTE, though the latter in
particular is still an emerging ﬁeld. What is less evident is a
consensus on what constitutes transparent and actionable evi-
dence of HTE. FDA standards require “substantial evidence,” that
is, similar results on primary end points from (generally) two
similar RCTs, to make a labeling claim for a pharmaceutical
product. The number of times two similar trials with the same
end points, however, can be conducted is limited, and practical
and statistical considerations limit the number of subgroups that
can be compared. Thus, to maximize the opportunities to derive
useful HTE evidence from RCTs, joint discussions among regu-
lators, payers, the pharmaceutical industry, as well as with other
stakeholders such as clinicians and patients, could bemost useful,
particularly if conducted during drug development to help specify
which patient subpopulations, treatment settings, disease phases,
or other aspects would be most important to explore in depth.
While regulator-industry consultation is routine, and early
industry-payer consultation has become more common of late,
more inclusive discussions are still uncommon.
An even more difﬁcult hurdle is establishing necessary and
sufﬁcient conditions for actionable HTE evidence from non-
randomized sources, even though these sources have the much
larger sample often needed to detect differences across patient
types. This is actually more like a triple jump—which data and
analysis methods are seen as being of sufﬁcient quality and
reliability for research purposes given lack of randomization, in
which treatment situations does the beneﬁt-risk situation justify
a departure from the usual substantial evidence standard, and
when can the various stakeholders agree that the evidence is
sufﬁcient for decision purposes? While a top-down, guideline-
based approach may be worth pursuing, it also seems that a
bottom-up, case-by-case, learn-by-doing approach may have
merit. Either way that it is done, there must ﬁrst be both agree-
ment and commitment from the different stakeholders that
generating reliable and actionable evidence on HTE is worth the
collaborative effort it will take to do so.
Evidence Utilization
Delivering the right care to the right patient has never been easy,
and despite the proliferation of data about patients, treatments,
and treatment effects, evidently still has signiﬁcant hurdles. Health
care within the United States has often been delivered without
standardized protocols and treatment; in places where treatment
protocols or consensus guidelines exist, patients have been shown
to not receive the recommended course of therapy across disease
areas [18]. With many innovative new therapies (medications,
devices, and regimens) becoming available, physicians can have
difﬁculty keeping abreast of the changing standard of care. In
addition, changes in the landscape of health care, including increa-
sed patient involvement, could presage a change in the nexus of
decision making regarding patient care, from physician to group
practice in accountable care organizations, or as part of larger
centers such as hospital centers, with uncertain effects on con-
sistency and continuity of care from individual physicians.
Despite these challenges to their ability to deliver high-quality
care, HCPs (including physicians and other afﬁliated delivery
workers) continue to play the primary caregiver role, with the
associated accountability. To deliver such care, HCPs must have
access to complete and timely information regarding patient
history and current health status, up-to-date treatment protocols
and guidelines, and information regarding meaningful patient
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vate payers have vested interests in ensuring that these factors
are also met to help ensure that the appropriate therapy gets to
the patient, at the correct time and in the appropriate setting.
Patients play a larger role in controlling and utilizing the
reports of their history, current health status, and treatment
outcomes, not only as more informed participants in their
interactions with providers but also through participation in
social networking health sites. Through social media, patients
have the opportunity to track and share their own treatment and
outcomes, including reports using standardized patient-reported
outcome instruments. These sites promote interactions with
other patients, provide suggestions for participation in clinical
trials, and, in some cases, even provide summary sheets to take
to doctor’s appointments [19,20]. Although these data collection
sites are outside the traditional health care delivery systems,
they represent a source of information useful not only in the
individual management of patient care but also as a repository of
longitudinal data. Such data could prove useful for identifying
new personal elements or even means of data capture that would
improve patient care. These methods are currently outside the
realm of providers, manufacturers, and payers of health care, but
are broadly representative of the changing landscape where
information is available in a more timely, broad-based, and
relatively uncontrolled manner. While current efforts focus
primarily on linking claims databases and EHR, future activities
should expand to include these valuable patient-centric data
sources, to provide a 360-degree perspective of health care
delivery and outcomes and enable more complete evidence
utilization during diagnosis and treatment.
Medication adherence is a good example of a behavioral
characteristic that differs by patient and can be fairly easily
tracked (i.e., reﬁlls); if such information is well utilized by pro-
viders and payers, patient outcomes could be improved. Certain
patient characteristics (income/insurance, “healthy adherer” pro-
ﬁle, previous adherence, disease severity) can be used to better
predict general adherence issues; product side-effect proﬁles and
co-pays (relative to other medications) may predict speciﬁc prod-
uct adherence; prescription reﬁll data can identify ongoing adher-
ence. Such evidence can be used by the provider to engage the
patient about medication problems or other adherence issues, and
perhaps lead to alternative medication choices. Payers can poten-
tially use their data to understand adherence determinants in
their own population —particularly sensitivities to co-pays—and
design their programs to better incentivize utilization of the
appropriate medication in the appropriate patient.
Darkow et al. [21] provide an illustration of how adherence data
have been utilized to improve treatment and outcomes [21]. In a
study of the use of imatinib (Gleevec®) for the treatment of chronic
myelogenous leukemia, the authors found that mean total health
care costs for patients with low medication possession ratios
(under 50%) were $131,357—more than three times the expendi-
tures of patients with medication possession ratios of 90% or
higher. UnitedHealthcare has reported that they established a
program to reach out to physicians of patients with chronic
myelogenous leukemia to assess the appropriateness of treating
these patients with imatinib. Simultaneously, patients were con-
tacted to help promote imatinib medication adherence. In general,
improved medication adherence is an area of common interest
among all health care stakeholders. The imatinib example illus-
trates that this can be the case even when the treatment itself is
associated with signiﬁcant health care expenditure.
Technology to facilitate interactions among patients, physi-
cians, and other HCPs is advancing rapidly. Nearly all health
plans now have Web sites that facilitate submission of claims for
reimbursement, as well as interactions between patients and
their physicians. Increasingly, applications for these samecapabilities are being developed for handheld devices. As these
technological developments continue to advance, the communi-
cation pathways among payers, patients, and physicians should
continue to expand.
Combining evidence generation and utilization: Collaborations
involving real-world data
A number of collaborations have formed to support not only
evidence generation but also utilization with respect to the clinical
effectiveness, safety, and value associated with pharmacothera-
pies and other health care interventions. These are partnerships
among organizations to combine data assets and/or analytics to
generate actionable insights. They include the following: Optum has announced the formation of Optum Labs, an
organization that is intended to be a collaboration among
various stakeholders (integrated delivery networks, private
and government payers, life sciences companies, academic
institutions, etc.) to tackle major health care problems. Optum
Labs, modeled after Bell Labs, the research and development
wing of AT&T, will provide a secure data environment, access
to a wide variety of health care datasets, high-speed comput-
ing and analytics, and deep expertise in statistical analysis of
observational data [22]. Wellpoint and IBM Watson are partnering to explore the
ability to provide physicians with evidence-based diagnosis
and treatment recommendations at the point of care on the
basis of clinical data, evidence from available research, and
other sources. This effort is an attempt to examine whether
the artiﬁcial intelligence and high-speed computing capabil-
ities of IBM Watson can be effectively applied in the health
care space [23]. At the other end of the spectrum, Archimedes
is an extremely sophisticated mathematical model that
attempts to simulate interactions among human physiology,
disease, interventions, and health care systems [24]. There are several examples of health plan collaborations with
research organizations and biopharmaceutical companies.
One of the ﬁrst of such partnerships was formed by Wellpoint,
its research arm HealthCore, and AstraZeneca to create a real-
world evidence and analytics platform to support evidence
generation to better understand treatment effectiveness,
safety, and value of existing therapies. This platform is also
being used to support the development of new therapies
through a better understanding of the natural history of
disease and where current therapies fall in the treatment
continuum [23]. Similarly, Competitive Health Analytics (a
wholly owned subsidiary of Humana) has entered into a
5-year partnership with—among others—Pﬁzer to design
and execute a research agenda focused primarily on the
delivery of health care to seniors [25]. Quintiles and Allscripts have a strategic partnership to use the
Allscripts electronic health record to develop software tools to
facilitate drug development [26].
Ultimately, all these partnerships reﬂect the realization that it is
futile to attempt to corner the market on data. Data are necessary,
but not sufﬁcient, for generating evidence that can then be utilized
in the real world. To answer the questions posed by payers,
regulators, providers, and patients, data sets need to be con-
structed that contain the relevant variables typically from integrated
data sources. Bigger is not necessarily better if key variables are
missing. Finally, appropriate methodologies need to be utilized.
The need to merge different types of data (e.g., claims data with
electronic clinical data, EMR, and tumor registry information), as
well as have access to the methodological expertise to properly
analyze the data, is a stimulus for many of the collaborations.
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medicinal products, biopharmaceutical companies conduct pro-
spective observational disease registries of real-world clinical
practice that could inform treatment protocols and guidelines.
An example of this is the National Registry of Myocardial
Infarction, initially sponsored as a postapproval safety study for
Genentech. Over time, the National Registry of Myocardial
Infarction became a repository that not only informed clinicians
regarding the standard of care but actually drove important
changes that shortened time to care and improved patient out-
comes [27]. Yet challenges remain in bringing all vested parties to
the table to discuss studies that would ultimately beneﬁt patient
outcomes. The relevant design and data interpretation contribu-
tions are not always included in these large-scale research
projects, which ultimately limits the application of the evidence
generated. Also, research sponsorship can lead to perception of
bias in design and analysis, which minimizes the impact in
presentation of results. Academic and governmental entities
conducting federally funded research face some requirements
to ensure transparency with regard to design, conduct, and
interpretation of results. Parties with a perceived vested interest
in the outcomes of studies they conduct (i.e., biopharma, private
payer, care centers) are increasingly imposing their own report-
ing standards and have recently begun to address external calls
for transparency (beyond regulatory submissions), which may
address the perception of deﬁciencies in methodology and biased
conclusions [28,29]. Collaborations, such as those between indus-
try and payers, can help mitigate concerns about transparency.
They could also improve analytic methods and reporting that
some feel taints unilaterally conducted research; ultimately, this
could lead to more rapid application of the results.
Economics
Properly implemented, HTE has the potential to improve efﬁ-
ciency of care while still providing incentives for drug develop-
ment and reimbursement, but economic considerations play an
important role in decisions about evidence generation and
utilization. From a pharmaceutical industry perspective, HTE
evidence, almost by deﬁnition, is likely to target a treatment to
a smaller set of patients and thus limit the market size. As such
one can model how it would shift the product’s demand curve to
the left, or make it steeper, or perhaps kink it or alter it in some
other fashion. In any case, the limited market size generally
becomes an important issue in drug development decisions in
the pharmaceutical industry. Drug development decisions are
based in part on the expected rate of return to investments in
research, which, in turn, is determined largely by expected
revenues versus development costs. To achieve revenues that
justify investment, reduced quantities sold may need to be offset
by higher prices and/or lower costs. Higher prices may be justiﬁed
because of the greater effectiveness expected from more targeted
treatments, though the elasticity of demand and/or cost-
effectiveness here may or may not be consistent with pricing
that would yield a reasonable return on investment, and other
payer-based considerations around pricing will come into play
[30]. Reduction of development costs may be feasible if identi-
ﬁcation of patients most likely to respond to a given treatment
can be done early enough to reduce trial sizes and increase the
probability of success during phase 3, given agreement to this
strategy by regulators. The need for development of companion
diagnostics would introduce other economic considerations, both
commercially and for HTA purposes [31]. Better identiﬁcation of
the most appropriate patients for treatment may also hasten
diffusion of the product to the target population, thus moving
revenues forward in time and increasing their net present value.
All these factors and more will inﬂuence industry decisions aboutevidence generation during drug development as well as post-
launch, from go/no-go decisions to the nature and size of clinical
trials.
From the payer’s perspective, economics plays a role in
utilizing evidence supporting personalized medicine on at least
two fronts as well. In terms of the price of the treatment per se,
willingness to pay is heavily inﬂuenced by the impact of the
treatment on the overall episode of care cost. As illustrated by the
Gleevec example noted earlier, commercial payers can certainly
be motivated to cover (and even encourage) therapies that lower
the total cost of an episode of care for targeted individuals—even
when such therapies are, themselves, very expensive. Also
important are the transaction costs of identifying the target
population in daily practice—not only any needed testing but
also the costs of educating physicians about such heterogeneity
and making the relevant patient information available to the
physician in real time, and possibly building some checks into
the reimbursement system. As electronic health information
systems improve, patient-speciﬁc treatment approaches become
much more feasible, but are still not costless. Payers may also
ﬁnd that implementing patient-speciﬁc treatment approaches
can change the uncertainty around patient outcomes— uncer-
tainty could increase if the evidence base is thinner than usual
label-based evidence or decrease if the targeted treatments truly
work better. Thus, changes to ﬁnancial risk due to the uncer-
tainty may need to be considered, while not discounting an
ethical or humanistic risk that may be incurred as well. If there
is a concern about increased risk, real-time monitoring of out-
comes and costs could be used to trigger stop or continuation
decisions, but this would incur costs as well. The kinds of
partnerships of payers with industry or other businesses dis-
cussed above can help to improve cost-efﬁciency, distribute the
cost burden, or reduce the business decision-related uncertainty
that can be economic obstacles to utilizing HTE evidence in
managing patient care.
Regulators can signiﬁcantly inﬂuence the economics of HTE in
several ways. From their perspective, reductions in sample size to
target certain populations, even if sensible for efﬁcacy determina-
tion, may be less desirable for provision of the safety database.
Because a drug can legally be prescribed for almost any patient by a
physician once it is approved, regulators prefer to have a large and
broad safety database before a drug is approved, depending on the
perceived beneﬁt-risk proﬁle of the product. In addition, some of
the more innovative and potentially efﬁcient trial designs, for
example, Bayesian adaptive designs, have proven acceptable in
phase 2 dose-ﬁnding studies but have been deemed less suitable
for pivotal phase 3 trials; choice of prior is one issue here. The FDA
has given guidance, however, for the use of Bayesian approaches
for medical devices [31]. In cases of HTE determination by comp-
anion diagnostics, requirements for joint testing of diagnostics and
therapeutics can inﬂuence the design and cost of clinical trials as
well as the business relationships between the test and therapy
manufacturers [7,32].
Finally, the economics of this situation, that is, the risk-reward of
generating new evidence, such as on HTE, from which other parties
can beneﬁt, has been approached in a game-theoretic, decision
analysis sense [33]. Another, better known, approach is that gen-
erated by value of information considerations [34]. In both cases,
there can be returns to society from incremental health care
evidence that transcend the economic return to an individual party
funding the research. While risk-sharing agreements and cover-
age-with-evidence development agreements are becoming more
common between industry and payers, there is certainly still
potential to exploit these mechanisms to incentivize the generation
and utilization of HTE evidence. Alternatively, government-based
mechanisms to generate the socially optimal amount of evidence
may be more practical in some situations, further supporting the
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) S 1 0 – S 1 5 S15other reasons for communication and collaboration across stake-
holders discussed above.Conclusions
Across the three realms of evidence generation, evidence utiliza-
tion, and economics that we have discussed, it is clear that any
given stakeholder acting individually may neither have sufﬁcient
incentive nor the resources necessary to properly pursue the study
of HTE for new products and use those results in the treatment of
patients. Collaborative efforts across these stakeholders to opti-
mize all types of evidence generation have begun and are likely to
be synergistic, but challenges in the collection of good outcomes
data and interpretation of nonrandomized data remain. Given
some consensus on what constitutes reliable evidence, better
information systems that communicate well with providers and
patients can then play an important role in utilizing evidence on
HTE to optimize individual patient treatments—true “personalized
medicine.” More efﬁciency in evidence generation and utilization,
as well as the clinical beneﬁt and long-term cost savings frommore
targeted and effective treatments, should help balance the eco-
nomic factors involved in developing and implementing such
treatments. Clear understandings among regulators, pharma, and
payers about high-value targets, methods to efﬁciently generate
and communicate information, and value propositions can lead to
“win-win” scenarios for patients, individual payers, the health care
system overall, and the future of drug development in producing
new medicines.
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